U.S. RESEARCH ROUNDUP- Cintas, Stryker, Zimmer Biomet Holdings

Altus Power

31/03/2023 08:01

March 31 (Reuters) - Wall Street securities analysts revised their ratings and price
targets on several U.S.-listed companies, including Cintas, Stryker and Zimmer Biomet Holdings
on Friday. 
    
    HIGHLIGHTS
                 * Cintas Corp  CTAS.O : Jefferies cuts to hold from buy
 
                 * Stryker Corp  SYK.N : Jefferies raises target price to $320 from
 $292
 
                 * Zimmer Biomet Holdings Inc  ZBH.N : Jefferies raises to hold from
 underperform
 
        
Following is a summary of research actions on U.S. companies reported by Reuters on Friday.
Stock entries are in alphabetical order. See bottom of the table for sector changes. 
    
                 * Altus Power Inc  AMPS.N : Evercore ISI cuts target price to $12 from $15
 
                 * Amylyx Pharmaceuticals Inc  AMLX.O : Mizuho starts with buy rating; $52 target
 price
 
                 * Avidity Biosciences Inc  RNA.O : Credit Suisse cuts target price to $30 from
 $35
 
                 * Brainstorm Cell Therapeutics Inc  BCLI.O : Maxim Group raises target price to
 $10 from $5
 
                 * Braze Inc  BRZE.O : BTIG raises target price to $40 from $34
 
                 * Braze Inc  BRZE.O : Canaccord Genuity raises target price to $38 from $33
 
                 * Braze Inc  BRZE.O : Piper Sandler raises target price to $40 from $33
 
                 * Candel Therapeutics Inc  CADL.O : Credit Suisse cuts target price to $7 from $8
 
                 * Cintas Corp  CTAS.O : Baird raises target price to $512 from $500
 
                 * Cintas Corp  CTAS.O : Jefferies cuts target price to $487 from $512
 
                 * Cintas Corp  CTAS.O : Jefferies cuts to hold from buy
 
                 * Dyne Therapeutics Inc  DYN.O : JP Morgan raises target price to $21 from $18
 
                 * Evgo Inc  EVGO.O : Evercore ISI cuts target price to $14 from $16
 
                 * Harpoon Therapeutics Inc  HARP.O : Piper Sandler cuts target price to $6 from
 $7
 
                 * IGM Biosciences Inc  IGMS.O : Jefferies cuts target price to $48 from $55
 
                 * IGM Biosciences Inc  IGMS.O : RBC cuts target price to $21 from $24
 
                 * Immunocore Holdings Plc  IMCR.O : Mizuho starts with buy rating; $70 target
 price
 
                 * Intellia Therapeutics Inc  NTLA.O : JP Morgan cuts target price to $79 from $82
 
                 * Myomo Inc  MYO.A : Ascendiant Capital cuts target price to $8.50 from $9
 
                 * National Beverage Corp  FIZZ.O : Jefferies raises target price to $40 from $38
 
                 * Presidio Property Trust Inc  SQFT.O : Colliers cuts target price to $1.10 from
 $1.50
 
                 * Regeneron Pharmaceuticals Inc  REGN.O : JP Morgan raises target price to $950
 from $900
 
                 * RH  RH.N : Baird cuts target price to $250 from $300
 
                 * Scynexis Inc  SCYX.O : Maxim Group raises target price to $10 from $7
 
                 * Sirius XM Holdings Inc  SIRI.O : Credit Suisse cuts target price to $4 from $5
 
                 * Skillz Inc  SKLZ.N : BTIG cuts target price to $0.40 from $0.71
 
                 * Skillz Inc  SKLZ.N : Canaccord Genuity cuts target price to $0.50 from $1.50
 
                 * Stryker Corp  SYK.N : Jefferies raises target price to $320 from $292
 
                 * Unifirst Corp  UNF.N : Baird cuts target price to $203 from $225
 
                 * Vigil Neuroscience Inc  VIGL.O : Mizuho starts with buy rating; $15 target
 price
 
                 * Y-Mabs Therapeutics Inc  YMAB.O : Canaccord Genuity cuts target price to $18
 from $20
 
                 * Zimmer Biomet Holdings Inc  ZBH.N : Jefferies raises target price to $130 from
 $115
 
                 * Zimmer Biomet Holdings Inc  ZBH.N : Jefferies raises to hold from underperform
 
                 * Zymeworks Inc  ZYME.O : JP Morgan raises target price to $9 from $8
 
    
  

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))